$381.01 +14.89 (%) Regeneron Pharmaceuticals Inc - NASDAQ

Oct. 21, 2014 | 04:00 PM

Partner Headlines

  1. Three Big Cap Leaders Remain In Buy Range

    IBD | Oct. 20, 2014 | 18:47PM EST
  2. UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patients With AD

    Benzinga | Oct. 20, 2014 | 07:06AM EST
  3. Regeneron's Eylea Tops Rivals

    IBD | Oct. 17, 2014 | 18:45PM EST
  4. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD | Oct. 17, 2014 | 11:27AM EST
  5. Stocks Power Higher At Open; Regeneron Vaults On Eylea Trial

    IBD | Oct. 17, 2014 | 10:58AM EST
  6. Benzinga's Volume Movers

    Benzinga | Oct. 17, 2014 | 10:45AM EST
  7. EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And Ranibizumab In NIH-Sponsored Diabetic Macular Edema Study

    Benzinga | Oct. 17, 2014 | 07:01AM EST
  8. LinkedIn, YY Among 5 Stocks With Top Fundamentals

    IBD | Oct. 16, 2014 | 08:02AM EST
  9. Apple, McKesson Among Big Caps In Trading Range

    IBD | Oct. 13, 2014 | 18:38PM EST
  10. Wall St. Expects Solid Q3 Profit Despite Global Blues

    IBD | Oct. 6, 2014 | 17:46PM EST
  11. Medical Stocks End Week On High Note, Biotechs Lead

    IBD | Oct. 4, 2014 | 08:02AM EST
  12. Alibaba Among 5 Stocks With Superior Long-Term Growth

    IBD | Oct. 1, 2014 | 19:52PM EST
  13. Stocks Move To Session Lows; Regeneron Rises On Drug Data

    IBD | Sep. 30, 2014 | 15:04PM EST
  14. Biotech Stocks Rebound On Strong Earnings, New Drugs

    IBD | Sep. 29, 2014 | 18:32PM EST
  15. Large-Cap Tech, Biotech Names Hang Tough In Shaky Market

    IBD | Sep. 29, 2014 | 18:32PM EST
  16. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD | Sep. 24, 2014 | 13:27PM EST
  17. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Inc Following DME Doc Event

    Benzinga | Sep. 18, 2014 | 10:51AM EST
  18. Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line

    IBD | Sep. 16, 2014 | 12:12PM EST
  19. Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks

    Benzinga | Sep. 16, 2014 | 08:19AM EST
  20. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD | Sep. 11, 2014 | 14:46PM EST
  21. Stocks Hold Modest Gains; FleetCor Reverses Higher

    IBD | Sep. 10, 2014 | 14:53PM EST
  22. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD | Sep. 10, 2014 | 13:25PM EST
  23. Novartis Drug Is Heartening

    IBD | Sep. 2, 2014 | 18:39PM EST
  24. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD | Sep. 2, 2014 | 18:04PM EST
  25. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD | Sep. 2, 2014 | 11:19AM EST
  26. Thin Gains Quickly Turn Mixed; Regeneron, Staples Surge Ahead

    IBD | Sep. 2, 2014 | 10:43AM EST
  27. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call

    Benzinga | Sep. 2, 2014 | 09:36AM EST
  28. Nasdaq, S&P 500 Rise In Lackluster Session; Tesla Gains

    IBD | Aug. 29, 2014 | 15:12PM EST
  29. Nasdaq Leads Quiet, Pre-Holiday Session; NXP Breaks Out

    IBD | Aug. 29, 2014 | 13:35PM EST
  30. Amgen edges up on trial results

    IBD | Aug. 28, 2014 | 18:42PM EST
  31. Stocks Indexes Fall Modestly, Shaking Off Ukraine Unrest

    IBD | Aug. 28, 2014 | 15:03PM EST
  32. Economic Data Fuel Another All-Time High For S&P 500

    IBD | Aug. 26, 2014 | 15:36PM EST
  33. Qihoo, Regeneron Among 5 Stocks With Top Fundamentals

    IBD | Aug. 21, 2014 | 13:25PM EST
  34. Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

    IBD | Aug. 18, 2014 | 13:46PM EST
  35. Drugmaker Q2 Profits Robust

    IBD | Aug. 5, 2014 | 18:51PM EST
  36. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  37. Deutsche Bank Raises Regeneron's Price Target To $425

    Benzinga | Aug. 5, 2014 | 15:30PM EST
  38. UPDATE: Regeneron Posts Upbeat Q2 Results

    Benzinga | Aug. 5, 2014 | 07:03AM EST
  39. Earnings Scheduled For August 5, 2014

    Benzinga | Aug. 5, 2014 | 05:34AM EST
  40. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD | Jul. 31, 2014 | 14:12PM EST
  41. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD | Jul. 30, 2014 | 17:00PM EST
  42. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD | Jul. 30, 2014 | 11:20AM EST
  43. Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples

    IBD | Jul. 30, 2014 | 10:31AM EST
  44. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD | Jul. 24, 2014 | 17:07PM EST
  45. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD | Jul. 10, 2014 | 17:22PM EST
  46. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD | Jul. 10, 2014 | 13:46PM EST
  47. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD | Jul. 10, 2014 | 12:07PM EST
  48. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study

    Benzinga | Jul. 10, 2014 | 10:03AM EST
  49. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 10, 2014 | 08:09AM EST
  50. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint

    Benzinga | Jul. 9, 2014 | 17:02PM EST
Trading Center